MENLO PARK, Calif., March 14, 2017 -- Landec Corporation (Nasdaq:LNDC) will hold a conference call on Wednesday April 5, 2017 at 8 a.m. Pacific time to discuss its results for the third quarter fiscal 2017. Financial results will be reported for the 2017 fiscal third quarter ended February 26, 2017 after market close on April 4, 2017.
Landec's President and CEO, Molly Hemmeter, will host the Conference Call with Gregory S. Skinner, Vice President and CFO. A question and answer period will follow the presentation.
Date: Wednesday April 5, 2017
Time: 8 a.m. Pacific time (11 a.m. Eastern time)
Toll Free Participant Dial-in Number: (844) 860-6243
U.S. and International Toll Number: (661) 378-9884
Conference ID: 87473692
Webcast: http://ir.Landec.com/events.cfm
The webcast will be available for 30 days through May 5, 2017.
A replay of the teleconference will be available for one week until midnight Eastern time, Wednesday April 12, 2017.
Toll free replay dial in: (855) 859-2056
International replay: (404) 537-3406
Replay passcode: 87473692
About Landec Corporation
Landec Corporation (NASDAQ:LNDC) is a leading innovator of diversified health and wellness solutions within the packaged natural food and biomaterial markets. Apio, Landec's food business, is the leader in branded, packaged fresh vegetables in North America, utilizing its proprietary BreatheWay® packaging technology to naturally extend the shelf life of fresh produce. Apio combines this technology with the capabilities of a large national fresh produce supplier to offer healthy fresh vegetable products under the Eat Smart® brand to consumers through club and retail grocery stores. Landec recently acquired O Olive Inc. that offers organic and natural olive oils and vinegars under the O brand. Lifecore Biomedical, Landec's biomaterial business, is a fully integrated Contract Development and Manufacturing Organization (CDMO) that offers expertise and capabilities in fermentation, specialty formulation, aseptic filling and final packaging for FDA regulated medical devices and drugs to customers for applications in a wide array of markets including Ophthalmic, Orthopedic and Oncology. For more information about the company, visit Landec's website at www.landec.com.
Media and Industry Contact: At the Company: Gregory S. Skinner Vice President Finance and CFO (650) 261-3677 Investor Relations: ICR, Inc. John Mills, Partner (646) 277-1254 [email protected]


Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube
Grok AI Faces Global Scrutiny Over Safeguard Failures and Illegal Content on X
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power
Short Interest Rises in Trump Media Stock After $6 Billion Merger Announcement
Bain Capital Moves to Acquire Majority Stake in Echo Marketing
Samsung Signals Comeback With HBM4 Chips as AI Market Heats Up
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 



